D.E. Shaw & Co
ATRA icon

D.E. Shaw & Co’s Atara Biotherapeutics ATRA Stock Holding History

D.E. Shaw & Co’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,484
Closed -$1.36M – 3712
2018
Q2 		$1.36M Buy
1,484
+1,200
+423% +$1.29M ﹤0.01% 2490
2018
Q1 		$277K Buy
+284
New +$259K ﹤0.01% 3191
2015
Q3 		– Sell
-400
Closed -$528K – 3716
2015
Q2 		$528K Buy
+400
New +$459K ﹤0.01% 3133

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's ATRA Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 41,360 shares — an estimated $530K sold.

D.E. Shaw & Co first reported a position in ATRA in Q1 2018 and held it in 17 quarters. The position peaked at $14.9M in Q3 2021. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 41,360 Atara Biotherapeutics shares in Q1 2024, an estimated $530K.
  • D.E. Shaw & Co first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 17 quarters.
  • D.E. Shaw & Co's Atara Biotherapeutics position peaked at $14.9M in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.